Lai Wei

Lai Wei

Auto-generated profile, based on publicly available information

Lai Wei

Enteric Neuroscience Program, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
RSRajan Singh
Rajan Singh
HZHannah Zogg
Hannah Zogg
LWLai Wei
Lai Wei
ABAllison Bartlett
Allison Bartlett
UGUday Ghoshal
Uday Ghoshal
Seungil RoSeungil Ro
Seungil Ro
Rajan Singh, Hannah Zogg, Lai Wei, Allison Bartlett, Uday C Ghoshal,* Singh Rajender, and Seungil Ro*. J Neurogastroenterol Motil 2021;27:19-34. https://doi.org/10.5056/jnm20149

23 March 2021 in JGH Open
Verified
Journal Article
Open access
PDF file
LWLai Wei
Lai Wei
RSRajan Singh
Rajan Singh
Seungil RoSeungil Ro
Seungil Ro
UGUday Ghoshal
Uday Ghoshal
Functional gastrointestinal disorders (FGIDs), currently known as disorders of gut–brain interaction, are emerging microbiota–gut–brain abnormalities that are prevalent worldwide. The pathogenesis of FGIDs is heterogeneous and is intertwined with gut microbiota and its derived molecule‐modulated mechanisms, including gut dysmotility, visceral hypersensitivity, gut immune abnormalities, abnormal secretion, and impaired barrier function. There has been phenomenal progress in understanding the role of gut microbiota in FGIDs by underpinning the species alternations between healthy and pathological conditions such as FGIDs. However, the precise gut microbiota‐directed cellular and molecular pathogeneses of FGIDs are yet enigmatic. Determining the mechanistic link between the gut microbiota and gastrointestinal (GI) diseases has been difficult due to (i) the lack of robust animal models imitating the various aspects of human FGID pathophysiology; (ii) the absence of longitudinal human and/or animal studies to unveil the interaction of the gut microbiota with FGID‐relevant pathogenesis; (iii) uncertainty about connections between human and animal studies; and (iv) insufficient data supporting a holistic view of disease‐specific pathophysiological changes in FGID patients. These unidentified gaps open possibilities to explore pathological mechanisms directed through gut microbiota dysbiosis in FGIDs. The current treatment options for dysbiotic gut microbiota are limited; dietary interventions, antibiotics, probiotics, and fecal microbiota transplantation are the front‐line clinical options. Here, we review the contribution of gut microbiota and its derived molecules in gut homeostasis and explore the possible pathophysiological mechanisms involved in FGIDs leading to potential therapeutics options.

30 July 2022 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
LWLai Wei
Lai Wei
RSRajan Singh
Rajan Singh
UGUday Ghoshal
Uday Ghoshal
Lai Wei, Rajan Singh, and Uday C Ghoshal. J Neurogastroenterol Motil 2022;28:357-75. https://doi.org/10.5056/jnm22008